Onesource Specialty Pharma Limited
25 Jul 2026
-
Hello, sir. So, we know about your FY28 guidance of US D160 million EBITDA. But can you highlight few initiatives you are taking for a longer term, which is beyond FY28? So, if we model for FY29 -30 for OneSource, do we think of growth trajectory longer term on 28 basis remains intact or otherwise? Can you give some clarity on that bit?
Read in transcript -
Okay, okay, sir. Thank you. That perfectly answered my question. Thank you.
Read in transcript